Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

This open-label, phase I/II study investigated the safety and efficacy of epratuzumab, a humanised anti-CD22 monoclonal antibody, in the treatment of patients with active primary Sjögren's syndrome (pSS). Sixteen Caucasian patients (14 females/2 males, 33–72 years) were to receive 4 infusions o...

Descripción completa

Detalles Bibliográficos
Autores principales: Steinfeld, Serge D, Tant, Laure, Burmester, Gerd R, Teoh, Nick KW, Wegener, William A, Goldenberg, David M, Pradier, Olivier
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779377/
https://www.ncbi.nlm.nih.gov/pubmed/16859536
http://dx.doi.org/10.1186/ar2018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779377/
https://www.ncbi.nlm.nih.gov/pubmed/16859536
http://dx.doi.org/10.1186/ar2018

Ejemplares similares